Tag Archives: Pharmaceutical law

In re Montgomery – “Unbounded” Inherency

In re Montgomery, App no. 2011-1376 (Fed. Cir. May 8, 2012) (a copy is available at the end of this post), a divided panel affirmed the Board’s decision that a claim to a “new use for an old compound” was … Continue reading

Posted in Anticipation | Tagged , , , , , , , , , , | Leave a comment

Supreme Court Reverses In Caraco Appeal

Today, in Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk, in an opinion authored by Justice Kagan (a copy can be found at the end of this post), the Court reversed the Fed. Cir.’s divided 2010 decision that an ANDA filer … Continue reading

Posted in Hatch-Waxman | Tagged , , , , , , , , , , , , , , | 1 Comment

Top 2011 IP Stories on Patents4Life

I spent a day or two looking back over the breaking IP news that resulted in posts on Patents4Life. I wrote most of them, but want to take a pause to thank regular contributors Paul Cole, Ron Schutz and Stefan … Continue reading

Posted in Miscellaneous | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

AMC v. Myriad – “Laws of Nature” Exception Does Not Include Isolated DNA

As noted in my last “flash” post, a divided three-judge Fed. Cir. panel (Judges Lourie, Bryson and Moore) issued an opinion holding that the isolated DNA sequences and the drug-screening method claimed by Myriad are patentable subject matter, not natural … Continue reading

Posted in Patentable Subject Matter | Tagged , , , , , , , , , , , , , , | 2 Comments